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Abstract. – OBJECTIVE: Autologous fat 
transfer (AFT) is commonly used to treat implant 
palpability and prevent fibrosis and thinning in 
mastectomy skin flaps. A major limit to this pro-
cedure is volume retention over time, leading 
to the introduction of fat enrichment with stro-
mal vascular fraction (SVF+AFT). Oncological 
concerns have been raised over the injection 
of an increased concentration of progenitors 
cells (ASCs) in the SVF. The aim of the study is 
to evaluate the long-term cancer recurrence risk 
of SVF+AFT cases compared to AFT, in patients 
undergoing Nipple Sparing Mastectomy (NSM). 
PATIENTS AND METHODS: A prospective 
study was designed to compare three groups of 
patients undergoing NSM followed by SVF+AFT, 
AFT or none (control group), after a two-stage 
breast reconstruction. Patients were strictly fol-
lowed-up for at least 5-years from the second 
stage reconstructive procedure. Loco-region-
al and systemic recurrence rate were evaluated 
over time as the primary outcome. Logistic re-
gression was used to investigate which factors 
were associated with recurrence events and in-
dependent variables of interest were: surgical 
technique, age above 50 years old, lympho-vas-
cular invasion, oncological stage, adjuvant or 
neoadjuvant chemotherapy, adjuvant radiother-
apy and adjuvant hormone therapy.
RESULTS: 41 women were included in G1 
(SVF+AFT), 64 in G2 (AFT), and 64 in G3 (con-
trol group). Loco-regional recurrence rate was 
2.4% for G1, 4.7% for G2, and 1.6% for G3. Sys-
temic recurrence was 7.3%, 3.1%, and 3.1%, re-
spectively. Among the variables included, there 
were no significant risk factors influencing a re-
currence event, either loco-regional or system-
ic. In particular, SVF+AFT (G1) did not increase 
the oncological recurrence. 
CONCLUSIONS: Our data suggest that both 
centrifuged and SVF-enhanced fat transfer have 
a similar safety level in comparison to patients 
who did not undergo fat grafting in breast recon-
struction after NSM. 
Key Words:
Stromal vascular fraction, SVF, Fat grafting, Adi-
pose derived stem cells, Oncological safety, Enriched 
fat grafting, Breast cancer. 
Abbreviations
AT: Adipose Tissue, ADSC: Adipo-Derived Stem Cells, 
ADRC: Adipo-Derived Regenerative Cells, SVF: Stro-
mal-Vascular Fraction, AFT: Autologous Fat Transfer, 
NSM: Nipple Sparing Mastectomy, TE: Tissue Expand-
er, CIN: Cervical Intraepithelial Neoplasia, VIN: Vul-
var Epithelial Neoplasia, CD: Cluster of Differentation, 
αSMA: Alpha-Smooth Muscle Actin, CT: Connective 
Tissue, IF: Increment Fold.
Introduction
Nipple sparing mastectomy (NSM) has 
gained a wide acceptance in the breast cancer 
scenario, due to its safety in terms of surgical 
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and oncological outcomes1-8. In this regard, 
the amazing psychological advantage of pre-
serving the nipple has led Veronesi to define 
this procedure a “conservative mastectomy”. 
This apparently paradoxical concept clearly 
opens doors to new horizons in breast recon-
struction9,10.
Skin flaps after NSM are often quite thin and 
could result in palpable and visible implants, 
skin flap necrosis, or other disappointing cos-
metic outcomes. Since 1990’s, Autologous Fat 
Transfer (AFT) has been adopted as a common 
surgical procedure for soft tissue augmentation, 
to improve the subcutaneous layer softness and 
give a natural appearance and breast contour 
to patients who underwent mastectomy. AFT 
represents an ideal tool to correct local defects 
and improve the coverage and skin quality of the 
mastectomy flaps. There is an increasing body 
of both observational and reported evidence1,11,12 
for cutaneous trophic changes following subcu-
taneous implantation of adipo-derived elements, 
yet there is a lack of evidence of long-term fat 
volume retention and graft survival over time. 
In recent years, investigation has been focusing 
attention on enriching the autologous adipose 
tissue graft with stem/progenitor cells isolated 
from the stromal vascular fraction (SVF) of 
AT, in order to improve its characteristics and 
long term persistence. Indeed, numerous pre-
clinical studies12-16, both on animal models and 
humans, as well as an emerging body of clinical 
data, suggest that adipose stem/progenitor cells 
(ASC) from the SVF, improve fat volume reten-
tion over time.
It has been suggested that the AT serves as 
a scaffold upon which more concentrated ASC 
can organize and differentiate, thus promoting 
the secretion of soluble factors that enhance an-
giogenesis, decrease apoptosis, and/or modulate 
the immune response17,18. However, the presence 
of ASC within AFT, either with enrichment or 
in the standard fashion, albeit in low concentra-
tion, has raised another important issue, namely 
the requirement for oncological evaluation of a 
possible recurrence risk19-22. Even though in the 
recent past such a risk has been reported for the 
AFT procedure in cases of ductal carcinoma in 
situ (DCIS)23, in 2016, Kronowitz et al24 showed 
no increase in rates of loco-regional recurrence, 
systemic recurrence or second breast cancer, 
resulting in supporting the oncologic safety of 
fat grafting in breast reconstruction. The only 
subgroup examined in which lipofilling was 
associated with an increased risk of loco-re-
gional recurrence was the subgroup treated with 
hormonal therapy, although the recurrence rates 
were low.
Delivering even more ASC to the tumor 
resection site may increase this fear of recur-
rence. The safety of SVF-enriched grafting for 
breast reconstruction has been largely debated 
but still there is no wide consensus as far. The 
aim of the study is to assess long-term oncolog-
ical safety in patients undergoing SVF + AFT 
treatment compared to the common procedure 
of autologous fat transfer (AFT), following 
NSM and breast reconstruction. A multi-arm 
clinical study was carried out to evaluate the 
incidence of local and systemic recurrences 
after NSM reconstruction among patients un-
dergoing SVF-AFT and AFT. A non-adipose 
tissue reconstruction was introduced as nega-
tive control group. 
Patients and Methods
Patients
In 2007 we designed a prospective, multi-
arm, single-center cohort study to compare 
and evaluate the effective oncological safety of 
SVF-enriched adipose tissue grafting. Patients 
diagnosed for breast cancer, who underwent 
NSM with breast reconstruction at our Institu-
tions, were divided in three groups. Although 
we routinely perform direct-to-implant recon-
struction, in this study we selected only patients 
eligible for two-stage breast reconstruction. The 
design of the study consisted in a first group 
of patients submitted to SVF-enriched adipose 
tissue grafting, or SVF-AFT (G1), a second 
group of patients submitted to the traditional 
Coleman’s lipofilling technique, or AFT (G2), 
and a third control group of patients that did not 
received any fat grafting procedure (G3). Inclu-
sion criteria of the study were: age between 18-
75 years old, history of NSM for a histologically 
proven Tis-T2N0-N2M0 breast adenocarcinoma 
in the previous 24 months, breast reconstruction 
performed by means of a Tissue Expander (TE) 
temporary breast prosthesis, active oncological 
follow-up (according to Associazione Italiana 
Oncologia Medica, AIOM, follow-up schedule 
guidelines, http://www.aiom.it) with no docu-
mented recurrences nor systemic disease at the 
time of enrollment, and signed informed consent 
form. Exclusion criteria were: medical history 
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of other malignant diseases (except for Cervical 
Intraepithelial Neoplasia – CIN – and Vulvar 
Intraepithelial Neoplasia – VIN –), including 
a previous breast cancer and NSM procedures, 
severe comorbidities (heart failure, hepatic and 
renal failure, collagen systemic diseases, psy-
chiatric disorders), and no active and scheduled 
follow-up. Whenever fat grafting was consid-
ered useful for the reconstruction, the patient 
was considered eligible for the study, if fitting 
all the inclusion and exclusion criteria. Control 
Group (G3) was collected from patients who did 
not require fat grafting upon enrollment. G3 
Patients did not undergo any fat graft procedure. 
Experimental Groups (G1 and G2) were subject 
to AFT+SVF (G1) or AFT alone (G2) at the time 
of second stage breast reconstruction. Subjects 
were not randomized and different procedures 
were performed dependent upon the operating 
reconstructive surgeon (CC for G1, DC, for G2), 
after a thorough evaluation with the patient, and 
a signed informed consent. 
A 5-years minimum follow-up, beginning 
from the second stage procedure, was planned 
including a standard AIOM schedule plus an 
ultrasound imaging of both breasts, once a year. 
MRI was limited to suspicious cases. Follow-up 
was calculated considering last visit update, 
according to each patient’s records. The study 
followed the ethical standards of human ex-
perimentation, according to the Declaration of 
Helsinki.
Surgical Procedures
Adipose Tissue Harvest
In both groups G1 and G2, patients were 
submitted to a fat graft procedure at the time of 
second stage reconstruction, during the expander/
implant exchange procedure25. All procedures 
were performed under general anesthesia. Li-
poaspiration was performed in either the ab-
domen, thighs, flanks, inner knees or gluteal 
regions, depending on patient’s body habitus and 
preferences. An antibiotic prophylaxis was ad-
ministered in all cases 30 minutes before surgical 
incisions.
Preparation of SVF-Enriched Fat Graft 
(Group 1, SVF+AFT)
The technique was conducted as previously 
described in the RESTORE-2 trial25. Aspi-
rated AT was divided in two parts. Part one 
was added to the Celution® system (Cyto-
ri Therapeutics; San Diego, CA, USA). The 
Adipose-Derived Regenerative Cells (ADRCs) 
were released from their bound matrix with 
the addition of a proteolytic enzyme reagent 
(Celase®, Cytori Therapeutics; San Diego, CA), 
washed to remove residual enzyme, and then 
concentrated within the closed automated sys-
tem in the operating room. The second part of 
lipoaspirate was purified with gravity sedimen-
tation/flotation. Part one (concentrated ADRCs 
– approximately 5 mL), was added and mixed 
to part two to create the ADRC-enriched fat 
graft. This enriched fat graft was then trans-
ferred in a sterile way to the surgical field using 
60 mL Toomey syringes.
Preparation of Standard Fat Graft 
(Group 2, AFT Alone)
Autologous lipoaspirate was centrifuged and 
processed according to the standard Coleman’s 
technique25.
Delivery of fat graft (Either 
Enriched or Aalone)
After tissue expander removal and definitive 
implant positioning via an inframammary crease 
access, a mastectomy flap dissection was per-
formed using a blunt cannula in a fan-shaped 
direction to include all over the breast mound, 
represented by the new implant. Dissection was 
carried out from the surgical incision, in the 
subcutaneous space between skin and implant 
capsula along with pectoralis muscle fibers. AFT 
was performed in this pre-tunneled plane using 
the Celbrush® (Cytori Therapeutics; San Diego, 
CA, USA) for G1 patients and standard cannulas 
for G2 patients. Antibiotic therapy was contin-
ued per os from the first post-operative day until 
drains were removed. 
Control Group
Patients belonging to Group 3 underwent the 
same pre, intra and post-operative treatment ex-
cept for the fat grafting procedure, which was not 
performed.
Follow-up
After discharge, patients were followed-up 
once a week for a month, then once a month 
for the following three months, and thereafter 
according to the oncological follow-up schedule 
mentioned above. Senior author (RD) revised 
outcomes and results.
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Statistical Analysis
Standard descriptive statistics were used to 
summarize data. Comparison of clinical char-
acteristics between the three groups of patients 
was performed by Kruskal Wallis rank test for 
continuous variables and Pearson’s x2-test (or 
Fisher’s exact test when appropriate) for categor-
ical variables. Logistic regression was used to 
investigate which factors were associated with 
recurrence events, either loco-regional or sys-
temic. Independent variables of interest were: 
surgical technique, age above 50 years old, 
lympho-vascular invasion, oncological stage, 
adjuvant or neoadjuvant chemotherapy, adjuvant 
radiotherapy, and adjuvant hormone therapy. A 
p-value less than 0.05 was considered statisti-
cally significant. All analyses were performed 
using STATA version 13 (StataCorp. 2013. Stata 
Statistical Software: Release 13. StataCorp LP, 
College Station, TX, USA).
Results
Between January 2008 and April 2011, 54 
patients were enrolled in G1 Group, 57 in G2, 
and 72 in G3. Four patients were lost to fol-
low-up in G1, two patients were lost in G2, and 
four were lost in G3. Nine patients enrolled 
in G1 declined to undergo the SVF-enriched 
fat grafting, choosing the standard fat grafting 
procedure and were therefore included in G2. 
Four patients were subsequently submitted to a 
fat graft procedure during follow-up in G3 and 
hence excluded from the study. In summary, 
patients included in the present analysis were 41 
women in G1, 64 women in G2, and 64 women 
in G3. A comparison of baseline patients char-
acteristics and oncological data is reported in 
Table I. No statistically significant difference 
was found among the groups. Median intervals 
from first stage procedure were 10, 9, and 12 
Table I. Baseline patient’s characteristics and oncological data.
 G1 G2 G3
Age, mean (range) 48.8 (34-61) 50.3 (33-69) 47.7 (33-60)
T   
  Tis 5 (7.3%) 9 (14.1%) 6 (9.4%)
  T1  16 (24.4%) 38 (59.4%) 26 (40.6%)
  T2 20 (68.3%) 17 (26.5%) 32 (50%)
DCIS component 12 (29.3%) 30 (46.9%) 19 (29.7%)
N   
  N0 20 (48.8%) 32 (50.0%) 33 (51.6%)
  N1 12 (29.3%) 26 (40.6%) 27 (42.2%)
  N2 9 (21.9%) 6 (9.4%) 4 (6.2%)
Grading    
  Not reported 3 (7.3%) 9 (14.1%) 5 (7.8%)
  1 2 (4.9%) 11 (17.2%) 9 (14.1%)
  2 20 (48.8%) 18 (21.1%) 23 (35.9%)
  3 16 (39.0%) 26 (40.6%) 27 (42.2%)
  Sentinel node biopsy  38 (92.7%) 52 (81.3%) 56 (87.5%)
  Axillary lymph nodes dissection 19 (46.3%) 32 (50.0%) 30 (46.9%)
  Lympho-vascular invasion 19 (46.3%) 23 (35.9%) 25 (39.1%)
  Adjuvant or neoadjuvant chemotherapy 28 (68.3%) 37 (57.8%) 35 (54.7%)
  Adjuvant hormone therapy 30 (73.2%) 43 (67.2%) 44 (68.8%)
  Adjuvant radiation therapy 17 (41.5%) 9 (14.1%) 4 (6.3%)
ER   
  Not reported 3 (7.3%) 9 (14.1%) 5 (7.8%)
  Negative 9 (22.0%) 12 (18.7%) 15 (23.4%)
  Positive 29 (70.7%) 43 (67.2%) 44 (68.8%)
PGR   
  Not reported 3 (7.3%) 7 (10.9%) 5 (7.8%)
  Negative 10 (24.4%) 16 (25.0%) 15 (23.4%)
  Positive 28 (68.3%) 41 (64.1%) 44 (68.8%)
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months for G1, G2, and G3 respectively. Median 
follow-up after the second procedure were 84 
months (range 60-96), 75 months (range 60-
96), and 72 months (range 60-96), respectively. 
The G1 Group demonstrated one local axillary 
lymph node recurrence (2.4%) (Table II). Three 
systemic recurrences were also recorded (7.3%) 
in this group: two bone metastases and one case 
of pulmonary plus liver metastases. Disease free 
survival (DFS) was 19, 22, and 25 months after 
the last reconstructive stage and 37, 34, and 38 
months after NSM. The G2 Group presented 
three local recurrences (4.7%) and two systemic 
recurrence events (3.1%). One of these patients 
presented both a local and systemic recurrence. 
A nodule at the level of the mastectomy flap was 
documented as a local recurrence 28 months 
after NSM and 15 months from the second stage 
and lipofilling procedure; two loco-regional ax-
illary lymph nodes recurrence were registered 
24 and 27 months from fat graft and 32 and 
40 months from NSM, respectively. Systemic 
recurrences were one pulmonary and one brain 
metastasis, occurring 14 and 24 months from the 
second stage and 22 and 32 from NSM, respec-
tively. Finally, the G3 Control group showed the 
presence of one local recurrence (1.6%) located 
in the nipple and two cases of systemic recur-
rences (3.1%): one bone and one bone plus liver 
metastasis. DFSs were 11, 13, 9 months from the 
second stage and 23, 34, 26 months from NSM 
respectively.
Regression analysis showed that among the 
oncological variables included, there were no 
significant risk factors, which would lead to a 
recurrence event, either loco-regional or sys-
Table II. Details of follow-up and recurrences.
 G1 G2 G3
Interval between first and second stage, median (range) 10 (1-22) 9 (5-14) 12 (8-15)
Follow-up after second procedure, median (range) 84 (60-96) 75 (60-96) 72 (60-96)
Loco-regional recurrences 1 (2.4%) 3 (4.7%) 1 (1.6%)
Systemic recurrences 3 (7.3%) 2 (3.1%) 2 (3.1%)
OR: Odds Ratio; CI: Confidence Interval; Ref.: Reference category.
Table III. Analysis of the risk of any recurrence (either local or systemic) related to several variables, including the three 
different surgical approaches.
  OR (95% CI), Adjusted OR (95% CI),
 Events  p-value p-value
Group   
  Group 1 4/41 (9.8%) 2.20 (0.47, 10.4) 0.320 1.92 (0.36, 10.31) 0.447
  Group 2 4/64 (6.3%) 1.36 (0.29, 6.32) 0.698 1.26 (0.25, 6.42) 0.778
  Group 3 3/64 (4.7%) Ref. Ref. 
Age   
  ≤ 50 4/106 (3.8%) Ref. Ref.
  > 50 7/63 (11.1%) 3.19 (0.89, 11.36) 0.074 3.40 (0.87, 13.25) 0.078
Stage   
  0-I 4/83 (4.8%) Ref. Ref.
  II-III 7/86 (8.1%) 1.75 (0.49, 6.22) 0.387 1.20 (0.29, 4.95) 0.797
Lympho-vascular invasion   
  No 5/102 (4.9%) Ref. Ref.
  Yes 6/67 (9.0%) 1.91 (0.56, 6.52) 0.303 2.16 (0.59, 7.87) 0.224
Adjuvant or neoadjuvant chemotherapy   
  No 4/69 (5.8%) Ref. Ref.
  Yes 7/100 (7.0%) 1.22 (0.34, 4.35) 0.756 1.30 (0.35, 4.90) 0.695
Adjuvant hormone therapy   
  No 4/51 (7.7%) Ref. Ref.
  Yes 7/117 (6.0%) 0.76 (0.21, 2.73) 0.678 0.85 (0.22, 3.37) 0.818
Adjuvant radiation therapy   
  No 8/139 (5.8%) Ref. Ref.
  Yes 3/30 (10.0%) 1.82 (0.45, 7.31) 0.399 1.14 (0.24, 5.50) 0.873
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temic. In particular, the adopted surgical tech-
nique does not represent a significant risk fac-
tor for recurrences (Table III). SVF+AFT (G1) 
did not increase the oncological recurrence, 
thus it seems to be safe from an oncological 
point of view. 
Discussion
Much attention has been given to the use of 
fat grafting as a source of cells with powerful 
biological effect in both cosmetic and recon-
structive surgery. However, the putative power-
ful biological effect of constitutive or additive 
adipo-derived cells may not be sufficient to se-
cure total engraftment and its consequent vol-
ume restoration, it might potentiate reparative, 
angiogenic or immunosuppressive mechanisms 
to increase oncological loco-regional recur-
rence. Indeed, fat grafting techniques continue 
to improve breast aesthetic outcomes in onco-
logically safe population, yet its adoption in 
postoncological breast reconstruction remains 
limited by two main concerns: unreliable fat 
volume retention over time and the increased 
risk of local recurrence in oncological patients. 
Stromal Vascular Fraction Enriched Fat Graft-
ing has been introduced providing well-docu-
mented improvements in volume retention12-14,16. 
However, minimal safety evidence can be re-
viewed in current literature. Volume retention 
rate and graft biology are strictly coupled. 
SVF and its ADRCs (both terminally differen-
tiated and progenitor pools) represent a com-
plex milieu, consisting of a heteregeneous cell 
subpopulations, vast secretome, and possibly 
biologically active subcellular elements. These 
include preadypocites, stem cells and micro-
vascular endothelial cells that have been shown 
to sustain preadipocyte viability in hypoxic 
conditions, thus promoting preadipocyte pro-
liferation and differentiation. The ADRCs pop-
ulation contains endothelial progenitors cells 
which provide, along with tissue macrophages, 
a secretome of proangiogenic and anti-apoptot-
ic growth factors30. SVF, for example, has been 
shown to hold factors such as IGF-1 which are 
involved with graft retention17,30-33. Nonetheless, 
there is still a second concern to be reviewed. 
It has been recently questioned the safety of 
“standard” fat grafting in patients with Ductal 
carcinoma in situ (DCIS). Such a concern may 
be even more substantial when considering a 
SVF enrichment with a considerable increase 
in stem cells and proangiogenic factors within 
the transplanted fat23.
It has been documented that stem/progenitor 
cells from the SVF increase the motility and 
promote epithelial to mesenchymal transition 
of breast cancer cells34,35, nevertheless the same 
SVF derived cells have been shown to inhibit 
the growth of numerous cancer cells36. The 
presence of protumorogenic and angiogenic fac-
tors in the graft requires a study of oncological 
safety. A number of anecdotal reports as well 
as some studies37,38 have furthered the claim of 
cancerous cell proliferation when cultured in 
the presence of stromal vascular fraction cells. 
They suggest that placing stem cells in close 
proximity to an environment, that once harbored 
cancerous growth, may result in increased onco-
logic recurrence. 
However, preclinical investigations remain 
controversial due to the models and cell types 
involved. On the other hand, Keramidas et al39 
report in humans shows interesting results about 
the inhibitory effect of mesenchymal stem cells 
on tumour growth39. A review of clinical stud-
ies40 focused on breast fat grafting described 
oncological outcomes in more than 2,000 pa-
tients with no significative increase of new or 
recurrent cancers.
Despite the encouraging results obtained by 
Tissiani et al41 reporting no loco-regional recur-
rences in patients undergoing SVF enriched fat 
grafts in secondary breast reconstruction, studies 
with a large number of patients and long-term 
follow up clinical data addressing this safety 
issue are currently lacking41. The cause of the 
debate on fat grafting safety is likely three-fold. 
First, some theoretical reasons (i.e., presence of 
protumorigenic factors within the graft) would 
suggest that fat grafting would influence cancer 
growth and metastasis. Second, nowadays the 
clinical researches on this topic have either small 
sample sizes and/or relatively short follow-up 
periods (i.e., the Perez-Cano trial, only 1 year). 
Last and more important, the results of laboratory 
studies have been interpreted beyond the context 
of their respective limitations; in fact, in-vitro 
culture system or preclinical animal model are 
not able to fully recapitulate the complexity of 
a unique clinical situation42-53. To our knowl-
edge, this is the study with the largest series of 
patients that aims at tracking SVF-enrichment 
oncological safety over a long-term follow-up, 
reporting a single-center experience of SVF-en-
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riched fat grafting in therapeutic NSM, in com-
parison to standard fat grafting and no fat graft 
control group54,55. The work showed no increase 
in rates of locoregional recurrence or systemic 
recurrence, supporting the oncologic safety of fat 
grafting and SVF-enhanced fat grafting in breast 
reconstruction. 
As reported by many authors, SVF-FAT en-
hanced graft is approximately two times rich-
er in stem/progenitor cells concentration than 
standard centrifuged fat graft, supporting our 
present series and previous experience with this 
procedure56-62.
Despite the uniqueness of the enrolled popula-
tions and the long-term follow-up of the present 
series, this study displays some limits: first of 
all the absence of randomization, and second, a 
relatively limited number of cases, being a sin-
gle-center series. 
Conclusions
Local and systemic recurrence rates suggest 
that both centrifuged and SVF-enhanced fat re-
construction have a similar safety level in com-
parison to patients who did not undergo fat 
grafting in breast reconstruction after NSM. A 
large prospective, randomized, multi-center clin-
ical study is still required to definitely assess the 
safety of fat grafting in a cancerous environment.
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